GATA2 and its influence on AML
Advances in AML understanding: APL therapy, immunotherapy and maintenance therapy
Alan Burnett et al.
Can we target AML with CAR T-cells?
What’s next for inotuzumab ozogamicin in ALL?
Myeloma UK – current focus and future directions